2012 Guest Speakers

News


2018 PROGRAMME PRESENTATIONS HERE

2018 ABSTRACT BOOKLET AVAILABLE HERE

2018 EVALUATION QUESTIONNAIRE AVAILABLE HERE

2018 PROGRAMME HERE

This course provides 6 CPD Credits in accordance with the CPD Scheme of the Royal College of Radiologists.

2018 Conference Sponsors Below


Platinum Sponsor
BXTAccelyon Logo

Silver Sponsors
BD and BARD logo
Eckert and Ziegler Logo
Elekta Company Logo

Bronze Sponsors
Augmenix logo logo
Bayer logo
Janssen logo
mim Software Company Logo
SeeDos logo
Varian medical systems logo

Additional Sponsor
BK Ultrasound logo
Oncology Imaging Systems logo
 
 
 
 

Guest Speakers 2012 Conference

 

Dr Gerard Morton (Toronto, Canada)

Gerard MortonGerard Morton is an Associate Professor at the University of Toronto and a Radiation Oncologist at the Sunnybrook Odette Cancer Centre, where he heads the brachytherapy program.

 

He attended medical school at University College Cork, and later trained in Clinical Oncology at St Luke's Hospital in Dublin. He completed Fellowship training in gynecologic oncology in Toronto.His main clinical and research interest is in prostate cancer and brachytherapy, with a particular focus on HDR brachytherapy and integration of imaging modalities.

 

He is past President of the Canadian Brachytherapy Group, a nucleus member of the Royal College of Physicians of Canada Radiation Oncology Specialty Committee, and chair of the Canadian Association of Radiation Oncologists ACURA Grant Panel.

 

He has published over 50 peer-reviewed papers, 10 book chapters, has been a visiting Professor in many countries, and has taught brachytherapy technique at many national and international workshops.

 

Professor Peter Hoskin (Mount Vernon, UK)

Peter HoskinPeter Hoskin has been consultant in clinical oncology at Mount Vernon Cancer Centre, Northwood UK since 1992. He is also Professor in Clinical Oncology at University College London. Research interests have ranged from palliative radiotherapy to the use of radiosensitisers and brachytherapy.

 

Current research programmes focus on the role of carbogen with nicotinamide and other drugs with radiotherapy, the interaction of vascular targeting agents with radiotherapy and the role of HDR brachytherapy in prostate cancer. He is chair of the prostate brachytherapy group PROBATE in ESTRO and Course organiser for the ESTRO prostate brachytherapy course.

 

Other appointments include Editor of Clinical Oncology, Section Editor for Brachytherapy and member of the Editorial Boards of Radiotherapy and Oncology and the Journal of Oncology.

 

Dr Stefan Machtens (Gladbach, Germany)

Dr Stefan Machtens Dr Machtens became the Head of the Department of Urology at Marien-Krankenhaus Bergisch Gladbach in 2006.

 

He has been a member of the German Society of Urology since 1995 and was awarded "Young Innovator in Urology" in 2000. Between 2003 - 2005 he was elected to the academic staff of Hanover Medical School In 2005 and was appointed to the Scientific Advisory Board of the Federal Association of prostate cancer support.

 

In 2007 Stefan assisted the German Society of Urology in writing the prostate cancer guidelines. He is a member of the teaching staff of both the European School of Urology and the European School of Radiation Oncology, is the recipient of 6 national and international scientific awards and had more than 150 abstracts, papers and book chapters in peer-reviewed journals.

 

Clinical and scientific interests include: Therapy of localized prostate cancer (Radical prostatectomy, Brachytherapy), Therapy of HRPC. PI in national chemotherapy trials on HRPC and Imaging in Prostate Cancer.

 

Dr Peter Grimm (Seattle, USA) - Prostate Cancer Center of Seattle

Peter Grimm

 

Professor Alvaro Martinez - William Beaumont Hospital, Michigan

Alvaro Martinez